Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text (PDF)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chapman, J.
Right arrow Articles by Korczyn, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chapman, J.
Right arrow Articles by Korczyn, A. D.
NEUROLOGY 1994;44:1683
© 1994 American Academy of Neurology

The risk of developing Creutzfeldt-Jakob disease in subjects with the PRNP gene codon 200 point mutation

Joab Chapman, MD, PhD, Joshua Ben-Israel, MD, Yochanan Goldhammer, MD and Amos D. Korczyn, MD, MSc

Departments of Neurology, Tel Aviv Medical Center (Drs. Chapman and Korczyn) and Sheba Medical Center (Dr. Goldhammer), Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv, Israel; and Medical Geriatric Center (Dr. Ben-Israel), Nethanya, Israel.

We determined the penetrance of the PRNP 200Lys mutation in the large cluster of Creutzfeldt-Jakob disease (CJD) cases among Jews of Libyan-Tunisian origin living in Israel, utilizing data from 52 carriers with definite or probable CJD and 34 unaffected mutation carriers. A life table analysis was carried out with development of CJD as the end point. The probability of developing CJD rose with age, fitting a second-order regression curve (R = 0.97, p < 0.001). The cumulative penetrance reached 50% at the age of 60 and 80% at 80 years. Including seven elderly possible CJD patients in the analysis made the penetrance approach 100% by age eighty. The penetrance of the mutation is high, and although age is a predominant influencing factor, other factors, such as gender, may also play a role.

Address correspondence and reprint requests to Professor A.D. Korczyn, Sackler Faculty of Medicine, Tel Aviv University, Ramat Aviv 69978, Israel.

Received February 2, 1993. Accepted in final form March 11, 1994.




This article has been cited by other articles:


Home page
Am. J. Neuroradiol.Home page
R.K. Fulbright, C. Hoffmann, H. Lee, A. Pozamantir, J. Chapman, and I. Prohovnik
MR Imaging of Familial Creutzfeldt-Jakob Disease: A Blinded and Controlled Study
AJNR Am. J. Neuroradiol., October 1, 2008; 29(9): 1638 - 1643.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
J. G. Safar, K. Kellings, A. Serban, D. Groth, J. E. Cleaver, S. B. Prusiner, and D. Riesner
Search for a Prion-Specific Nucleic Acid
J. Virol., August 15, 2005; 79(16): 10796 - 10806.
[Abstract] [Full Text] [PDF]


Home page
J. Virol.Home page
M. R. Scott, D. Peretz, H.-O. B. Nguyen, S. J. DeArmond, and S. B. Prusiner
Transmission Barriers for Bovine, Ovine, and Human Prions in Transgenic Mice
J. Virol., May 1, 2005; 79(9): 5259 - 5271.
[Abstract] [Full Text] [PDF]


Home page
Br Med BullHome page
P. Gambetti, Q. Kong, W. Zou, P. Parchi, and S. G Chen
Sporadic and familial CJD: classification and characterisation
Br. Med. Bull., June 1, 2003; 66(1): 213 - 239.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
A. L. Taratuto, P. Piccardo, E. G. Reich, S. G. Chen, G. Sevlever, M. Schultz, A. A. Luzzi, M. Rugiero, G. Abecasis, M. Endelman, et al.
Insomnia associated with thalamic involvement in E200K Creutzfeldt-Jakob disease
Neurology, February 12, 2002; 58(3): 362 - 367.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
J. A. Mastrianni, S. Capellari, G. C. Telling, D. Han, P. Bosque, S. B. Prusiner, and S. J. DeArmond
Inherited prion disease caused by the V210I mutation: Transmission to transgenic mice
Neurology, December 26, 2001; 57(12): 2198 - 2205.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
S. B. Prusiner
Prions
PNAS, November 10, 1998; 95(23): 13363 - 13383.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
S. B. Prusiner
Prion Diseases and the BSE Crisis
Science, October 10, 1997; 278(5336): 245 - 251.
[Abstract] [Full Text]


Home page
Proc. Natl. Acad. Sci. USAHome page
K. Kaneko, L. Zulianello, M. Scott, C. M. Cooper, A. C. Wallace, T. L. James, F. E. Cohen, and S. B. Prusiner
Evidence for protein X binding to a discontinuous epitope on the cellular prion protein during scrapie prion propagation
PNAS, September 16, 1997; 94(19): 10069 - 10074.
[Abstract] [Full Text] [PDF]


Home page
Cold Spring Harb Symp Quant BiolHome page
S.B. Prusiner
Molecular Biology and Genetics of Prion Diseases
Cold Spring Harb Symp Quant Biol, January 1, 1996; 61(0): 473 - 493.
[Abstract] [PDF]


Home page
J. Biol. Chem.Home page
Y. Zhang, W. Swietnicki, M. G. Zagorski, W. K. Surewicz, and F. D. Sonnichsen
Solution Structure of the E200K Variant of Human Prion Protein. IMPLICATIONS FOR THE MECHANISM OF PATHOGENESIS IN FAMILIAL PRION DISEASES
J. Biol. Chem., October 20, 2000; 275(43): 33650 - 33654.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1994 by AAN Enterprises, Inc.